Copertina

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jimmy Wen, Ubaid Ansari, Mouhamad Shehabat, Zaid Ansari, Burhaan Syed, Adam Razick, Daniel Razick, Muzammil Akhtar, Eldo Frezza
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Journal of Diabetes
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Selective Androgen Receptor Modulators (SARMs) Effects on Physical Performance: A Systematic Review of Randomized Control Trials
di: Jimmy Wen, et al.
Pubblicazione: (2024)

Favorable Short-Term Outcomes of Matrix-Associated Autologous Chondrocyte Implantation for Osteochondral Lesions of the Talus: A Systematic Review
di: Jimmy Wen, et al.
Pubblicazione: (2025)

Geographic impact on relative locations of interventional spine and musculoskeletal medicine fellowships relative to residency and first job placement
di: Jimmy Wen, et al.
Pubblicazione: (2025)

An Update on GLP‐1 Receptor Agonists
di: Zachary Bloomgarden
Pubblicazione: (2025)

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
di: Jirawan Vienghirun, et al.
Pubblicazione: (2026)

Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
di: Fei Lu
Pubblicazione: (2026)

GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation
di: Haisheng Wu, et al.
Pubblicazione: (2026)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
di: Roberta Scairati, et al.
Pubblicazione: (2026)

Reply: Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
di: Zhiyuan Cheng, et al.
Pubblicazione: (2026)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
di: Inyoung Hwang, et al.
Pubblicazione: (2026)

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
di: A. G. Barajas, et al.
Pubblicazione: (2025)

Weight Loss Outcomes Between GLP ‐1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta‐Analysis and Meta‐Regression
di: Muhammad Tahir, et al.
Pubblicazione: (2026)

GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
di: Cynthia F. X. C. A. Silva, et al.
Pubblicazione: (2026)

Interpreting Lean Mass Changes During Tirzepatide‐Induced Weight Loss: Beyond Quantitative Metrics
di: Tuba Uyanık
Pubblicazione: (2026)

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
di: Lasin Ozbek, et al.
Pubblicazione: (2026)

Impact of GLP ‐1 Receptor Agonist Discontinuation on Liver‐Related Parameters: A Systematic Review and Meta‐Analysis
di: Matheus Souza, et al.
Pubblicazione: (2026)

Searching the Crystal Ball for Tailored GLP‐1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity
di: Asia Saturnino, et al.
Pubblicazione: (2024)

Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
di: Rayanne Santos de Paulo, et al.
Pubblicazione: (2026)

Beyond GLP ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
di: Mikhail Khachaturov, et al.
Pubblicazione: (2026)

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
di: Tahmid Hussain, et al.
Pubblicazione: (2026)

Glycated Haemoglobin Levels and Its Effect on Outcomes in Cardiac Surgery
di: Daniyal Matin Ansari
Pubblicazione: (2022)

Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
di: Patrice Carter, et al.
Pubblicazione: (2025)

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
di: Yazan Alhamdan, et al.
Pubblicazione: (2026)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
di: Yue Yin, et al.
Pubblicazione: (2025)

GLP ‐1, GIP , and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids
di: Carlijn A. Hoekx, et al.
Pubblicazione: (2026)

Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
di: Ahmed Y. Azzam, et al.
Pubblicazione: (2025)

The location of the centre of the proximal quadriceps tendon in kinematically aligned total knee arthroplasty is not associated with poor outcome scores or symptomatic patellar instability
di: Daniel Razick, et al.
Pubblicazione: (2024)

Beyond GLP ‐1
di: Zachary Bloomgarden
Pubblicazione: (2026)

The Gastrointestinal Safety of Orforglipron, a GLP ‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
di: Ahmed W. Hageen, et al.
Pubblicazione: (2026)

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
di: Sanbao Chai, et al.
Pubblicazione: (2024)

Methodological Concerns Regarding BMI Imbalance and Competing Risks in a Head‐to‐Head Comparison of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists for Incident Dementia
di: Shio‐Shin Jean, et al.
Pubblicazione: (2026)

Identifying Provider Prescribing Practices for GLP‐1RAs and SGLT‐2is in Patients With Type 2 Diabetes to Address Pharmacoinequity
di: Parnnate Wongsirisakul, et al.
Pubblicazione: (2026)

RETRACTION : Effects of GLP ‐1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis Based on Randomized Controlled Trials
Pubblicazione: (2026)

Cardiometabolic Profiles and Treatment Trajectories of GLP ‐1 Receptor Agonist Users With Obstructive Sleep Apnea: Real‐World Evidence From a Large Private Healthcare Cohort in Poland
di: Klaudia Nowak, et al.
Pubblicazione: (2026)

Usefulness of Once‐Weekly GLP‐1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
di: Tomohiko Kimura, et al.
Pubblicazione: (2024)

Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP ‐1 Receptor Agonists: A Machine Learning–Based Analysis of a Large Real World Cohort
di: Pierpaolo Falcetta, et al.
Pubblicazione: (2026)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
di: Iskandar Idris
Pubblicazione: (2024)

Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?
di: Zachary Bloomgarden
Pubblicazione: (2024)

Residual Gastric Content in Hospitalised GLP ‐ 1RA Users: Considerations for Interpretation
di: Jiajia Xia
Pubblicazione: (2026)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
di: Tommaso Bucci, et al.
Pubblicazione: (2025)